Author Search Results

1

Ethnic sensitivity assessment of the antibody–drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer

by: Li, Chunze
Published in: Cancer chemotherapy and pharmacology (2016)

lizenzpflichtig

electronic Article

2

Exposure–response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane

by: Li, Chunze
Published in: Cancer chemotherapy and pharmacology (2017)

lizenzpflichtig

electronic Article

3

Clinical pharmacology strategies in supporting drug development and approval of antibody–drug conjugates in oncology

by: Liu, Stephanie N.
Published in: Cancer chemotherapy and pharmacology (2021)

Other Authors: “...Li, Chunze...”
kostenfrei

electronic Article

4

Correction to: Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC)

by: Chen, Shang-Chiung
Published in: Cancer chemotherapy and pharmacology (2017)

Other Authors: “...Li, Chunze...”
lizenzpflichtig

electronic Article

5

Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC)

by: Chen, Shang-Chiung
Published in: Cancer chemotherapy and pharmacology (2017)

Other Authors: “...Li, Chunze...”
lizenzpflichtig

electronic Article

6

Comparative Effects of Fibrates on Drug Metabolizing Enzymes in Human Hepatocytes

by: Prueksaritanont, Thomayant
Published in: Pharmaceutical research (2005)

Other Authors: “...Li, Chunze...”
lizenzpflichtig

electronic Article

7

A Pharmacometric Analysis of Patient-Reported Outcomes in Breast Cancer Patients Through Item Response Theory

by: Schindler, Emilie
Published in: Pharmaceutical research (2018)

Other Authors: “...Li, Chunze...”
kostenfrei

electronic Article

8

Correction to: Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study

by: Wang, Bei
Published in: Cancer chemotherapy and pharmacology (2021)

Other Authors: “...Li, Chunze...”
lizenzpflichtig

electronic Article

9

Population pharmacokinetic and exposure–response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive early breast cancer

by: Quartino, Angelica L.
Published in: Cancer chemotherapy and pharmacology (2015)

Other Authors: “...Li, Chunze...”
kostenfrei

electronic Article

10

Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study

by: Wang, Bei
Published in: Cancer chemotherapy and pharmacology (2021)

Other Authors: “...Li, Chunze...”
kostenfrei

electronic Article

11

Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma

by: Shemesh, Colby S.
Published in: Cancer chemotherapy and pharmacology (2020)

Other Authors: “...Li, Chunze...”
kostenfrei

electronic Article

12

$Population Pharmacokinetics and Exposure–Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma$

Population Pharmacokinetics and Exposure–Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma

by: Samineni, Divya
Published in: Advances in therapy (2021)

Other Authors: “...Li, Chunze...”
kostenfrei

electronic Article

13

Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer

by: Lu, Dan
Published in: Cancer chemotherapy and pharmacology (2019)

Other Authors: “...Li, Chunze...”
lizenzpflichtig

electronic Article

14

$Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma$